ClinicalTrials.gg
Not yet recruitingNCT07674199Updated Jun 29, 2026

EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT

An Early Phase 1 interventional study of Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection) in Patients After Hematopoietic Stem Cell Transplantation, sponsored by The General Hospital of Western Theater Command. Not yet recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by The General Hospital of Western Theater Command · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to investigate the efficacy of the EBV mRNA vaccine (WGc-0401 injection) in preventing EBV-related diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to evaluate the safety and efficacy of this vaccine in patients following allo-HSCT.

The main study questions are:

  1. The incidence of grade III-IV acute graft-versus-host disease (aGVHD) within 100 days, and the occurrence of ≥ grade 3 adverse events (AEs) that are possibly or definitely related to the vaccine, in patients receiving EBV mRNA vaccination after allo-HSCT.
  2. To determine the optimal biological dose (OBD) of the EBV mRNA vaccine in patients after allo-HSCT among the dose levels of 25μg, 50μg, 75μg, or 100μg.
  3. EBV-ELISpot levels, the incidence of EBV viremia (EBV DNAemia), the incidence of post-transplant lymphoproliferative disorders (PTLD), disease relapse rate during follow-up, non-relapse mortality (NRM), and immunogenicity indicators (IFN-γ+ T cells, immune cell analysis, cytokine profiles, EBV glycoprotein antigen antibodies).

Participants will:

  1. Receive three intramuscular injections of the EBV mRNA vaccine on days 30, 44, and 81 after allogeneic hematopoietic stem cell transplantation (d30, d44, d81).
  2. Be hospitalized for at least 72 hours after each vaccination for close monitoring (with a focus on CRS and aGVHD), and undergo intensive safety assessments throughout the dose-escalation period (at least 28 days).
  3. Return for clinical visits on days 7 (d37, d51, d88), day 14 (d58), and day 180 (d180) after vaccination for EBV-ELISpot, EBV-DNA quantification, and immunogenicity testing, with continued long-term follow-up to evaluate safety and the persistence of vaccine-induced immune responses.
02

Conditions studied

  • Patients After Hematopoietic Stem Cell Transplantation

Keywords

  • HSCT
03

In context

Lead sponsor

The General Hospital of Western Theater Command is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥14 years, regardless of gender;
  • Patients undergoing hematopoietic stem cell transplantation;
  • Voluntary participation in the clinical study and signing of the form.

Exclusion criteria

Exclusion Criteria:

  • History of vaccine allergy;
  • Presence of active acute (aGVHD) at screening;
  • Severe impairment of cardiac, hepatic, or renal function;
  • Body temperature >38°C within 72 hours prior to enrollment;
  • Inability to communicate reliably with the investigator or unlikely to comply with study requirements;
  • Any other condition deemed by the investigator to make the patient unsuitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    EBV mRNA Vaccine (WGc-0401)

    Drug: EBV mRNA vaccine (WGc-0401 injection) Description: Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection)

    Biological: Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection)

  • No intervention
    Observation Group

Interventions

  • BiologicalIntramuscular injection of EBV mRNA vaccine (WGc-0401 injection)

    Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection)

06

What researchers measure

Primary outcomes

  1. Incidence of grade III-IV acute graft-versus-host disease (aGVHD)

    Assessed according to the modified Glucksberg criteria (or the MAGIC criteria), with clinical staging comprehensively determined by the attending physician based on the involvement of skin, upper and lower gastrointestinal tract, and liver.

    Time frame: Up to 100 days after HSCT

  2. Incidence of grade ≥3 treatment related adverse events (TRAEs)

    AEs graded per CTCAE v6.0. Grade ≥3 AEs with causality assessed as possibly, probably, or definitely related to the vaccine are captured. Systematic AE assessment at each visit covers: local injection site reactions, systemic symptoms (fever, fatigue), laboratory abnormalities (cytopenias, transaminitis), and hypersensitivity. Causality determined by investigator based on temporal association, biological plausibility, and exclusion of other causes.

    Time frame: Up to 180 days after HSCT

Secondary outcomes

  1. Incidence of EBV viremia

    EBV-DNA load measured in plasma by quantitative real-time PCR (qPCR). Abnormal viremia defined as either: (1) ≥10³ copies/mL on two consecutive measurements (with an interval of at least 1 day), or (2) a single measurement ≥10⁴ copies/mL.

    Time frame: From Day 30 to Day 180 post-transplant

  2. EBV-specific T-cell response measured by IFN-γ ELISpot

    EBV-specific T-cell immune response measured by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) assay using peripheral blood mononuclear cells (PBMCs) stimulated with EBV peptide pools (e.g., LMP2, EBNA1, BZLF1). Results expressed as spot-forming cells (SFC) per 2×10⁵ PBMCs. Positive response defined as ≥25 SFC/2×10⁵ PBMCs and at least 2-fold above negative control. Samples collected at protocol-specified time points.

    Time frame: Post-transplant days 37, 44, 51, 58, 81, 88, and 180

  3. Incidence of post-transplant lymphoproliferative disorders (PTLD)

    PTLD confirmed by tissue biopsy per WHO classification. EBV status by EBER in situ hybridization. Subtypes: early lesions, polymorphic, monomorphic, or classic Hodgkin lymphoma-type. Clinical presentation, sites, and response recorded.

    Time frame: From HSCT (day 0) through 12 months post-transplant

  4. Underlying disease relapse rate

    Relapse defined as recurrence of primary disease post-HSCT. Confirmed by bone marrow (≥5% blasts), flow cytometry, cytogenetics/FISH, molecular markers, or extramedullary biopsy/imaging as indicated.

    Time frame: Day 0 to 12 months post-HSCT

  5. EBV vaccine-induced humoral and cellular immune responses

    Immunogenicity indicators: (1) EBV-specific antibodies (VCA-IgG, EBNA1-IgG) by ELISA; (2) EBV-specific T-cell responses by IFN-γ ELISpot; (3) serum cytokines/chemokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, MCP-1) by multiplex assay. All samples processed at central lab.

    Time frame: Pre-vaccination (baseline) and 24h post-vaccination (antibodies/T-cells); pre-vaccination and 6h, 24h post-vaccination (cytokines). Per vaccination dose.

  6. Non-relapse mortality (NRM)

    Death from any cause except relapse/progression post-HSCT. Causes: infection, organ failure, GVHD, second malignancy, hemorrhage, other transplant-related causes. Deaths without documented relapse included as NRM.

    Time frame: Cumulative NRM at day 100 and 12 months post-HSCT

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Describe which specific IPD will be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2030, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 29, 2026
StartEst.
Jun 18, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07674199
Lead sponsor
The General Hospital of Western Theater Command
Responsible party
Zhangshan (Hematologist, The General Hospital of Western Theater Command) — Principal investigator
First posted
Jun 29, 2026
Start date
Jun 18, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Jun 29, 2026

Study contacts

shan zhang
Contact
952750480@qq.com
+8618382430038
hai yi
Contact
yihaimail@163.com
+8613699418229

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion